| 05/09/2008 03:00 AM |
| VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults |
|
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day.
|
| 05/08/2008 06:00 AM |
| Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms |
|
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
|
| 05/08/2008 12:00 AM |
| OROS(R) Methylphenidate In Adults With ADHD: New Insights |
|
Although once considered to be a disorder only seen in children, Attention Deficit Hyperactivity Disorder (ADHD) is now known to be a condition associated with a wide range of functional impairments throughout the lifespan(1). In the US, the overall prevalence of ADHD in adults is estimated to range between 3.4% and 4.4%(2), and between 30 and 70% of children with ADHD continue to exhibit symptoms into adult years(3).
|
| 05/08/2008 12:00 AM |
| New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA(TM) (methylphenidate Transdermal System), Offered ADHD Symptom Control For 12 Months |
|
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
|
| 05/02/2008 01:00 AM |
| Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting |
|
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.
|
| 04/28/2008 02:00 AM |
| Sensory Treatment Reduces Autistic Mannerisms |
|
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
|
| 04/27/2008 03:00 AM |
| Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties |
|
A mind is a terrible thing to waste, but humans may have even less to work with than previously thought. University of Missouri researchers found that the average person can keep just three or four things in their "working memory" or conscious mind at one time. This finding may lead to better ways to assess and help people with attention-deficit and focus difficulties, improve classroom performance and enhance test scores.
|
| 04/24/2008 12:00 AM |
| FDA Approves VYVANSE(TM) (lisdexamfetamine Dimesylate), The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults |
|
Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global specialty biopharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
|
| 04/22/2008 03:00 AM |
| Heart Tests Should Be Carried Out Before Treatment With Stimulant Drugs For Children With ADHD |
|
Children with attention deficit hyperactivity disorder (ADHD) should get careful cardiac evaluation and monitoring - including an electrocardiogram (ECG) - before treatment with stimulant drugs, a new American Heart Association statement recommends.The scientific statement on Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving Stimulant Drugs is published online in Circulation: Journal of the American Heart Association.
|
| 04/21/2008 12:00 AM |
| Medication Improves Driving Ability ADHD Patients |
|
The use of the medication methylphenidate considerably improves the driving ability of people with ADHD. This was shown in research done by Joris Verster of Utrecht University, The Netherlands. The study will appear in the May 2008 issue of Journal of Psychopharmacology.People with ADHD are often prescribed methylphenidate (brand name Ritalin) to counteract hyperactive behavior and attention dysfunction that may negatively affect their driving ability.
|
| 03/31/2008 04:00 AM |
| Stimulant Treatment For Young Children With ADHD Does Not Lead To Increased Risk Of Substance Abuse In Early Adulthood |
|
Treatment of children with stimulant medications for attention-deficit/hyperactivity disorder (ADHD) does not increase the risk of substance abuse later in adolescence and early adulthood.
|
| 03/31/2008 03:00 AM |
| Encouraging Preschool Kids To Talk To Themselves |
|
Parents should not worry when their pre-schoolers talk to themselves; in fact, they should encourage it, says Adam Winsler, an associate professor of psychology at George Mason University. His recent study published in Early Childhood Research Quarterly showed that 5-year-olds do better on motor tasks when they talk to themselves out loud (either spontaneously or when told to do so by an adult) than when they are silent.
|
| 03/21/2008 02:00 AM |
| Young Hyperactive Girls More Likely To Have Serious Problems As Adults |
|
Young girls who are hyperactive are more likely to get hooked on smoking, under-perform in school or jobs and gravitate towards mentally abusive relationships as adults, according to a joint study by researchers from the Université de Montréal and the University College London (UCL).
|
| 03/20/2008 03:00 AM |
| Studying ADHD In Youth Of Different Races |
|
The research in the article looked at childhood ADHD in underrepresented minorities, reviewing controversy around evaluation, diagnosis, and obstacles faced by families, ending with recommendations for assessment and treatment.
|
| 03/17/2008 03:00 AM |
| Increased Risk For Eating Disorders Found In Adolescent Girls With ADHD |
|
Girls with attention deficit hyperactivity disorder stand a substantially greater risk of developing eating disorders in adolescence than girls without ADHD, a new study has found."Adolescent girls with ADHD frequently develop body-image dissatisfaction and may go through repeating cycles of binge eating and purging behaviors that are common in bulimia nervosa," said University of Virginia psychologist Amori Yee Mikami, who led the study.
|
| 03/16/2008 01:00 PM |
| ADHD Treatment For Children Different Between Specialties, Australia |
|
Standardisation of diagnosis and treatment of ADHD is needed to ensure consistency between treatment by psychiatrists and paediatricians, according to a study in the latest Medical Journal of Australia.
|
| 03/11/2008 01:00 AM |
| Auriga Laboratories Announces FDA Approval Of Liquadd (TM) Oral Solution For The Treatment Of ADHD And Upcoming Product Launch |
|
Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd™ (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD). The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually. Dextroamphetamine is one of the most frequently prescribed molecules for the treatment of ADHD.
|
| 03/03/2008 02:00 AM |
| ADHD Stimulant Treatment Has No Effect On Risk Of Future Substance Abuse |
|
A new study finds that the use of stimulant drugs to treat children with ADHD has no effect on their future risk of substance abuse. The report, which will appear in the American Journal of Psychiatry and has been issued online, assessed more than 100 young men 10 years after they had been diagnosed with ADHD and is the most methologically rigorous analysis of any potential relationship between stimulant treatment and drug abuse.
|
| 03/03/2008 02:00 AM |
| Methylphenidate Can Have Sleep Benefits In Adults With ADHD |
|
Treatment with methylphenidate (MPH) appears to have beneficial effects on sleep parameters in adults with ADHD, including increased sleep efficiency and a feeling of improved restorative value of sleep, according to a study published in the March 1 issue of the journal SLEEP.
|
| 02/21/2008 11:00 PM |
| For Boys With Fragile X Sydrome And ADHD, New Hope Found In Non-Stimulant Medication |
|
The most common hereditary form of hereditary mental retardation isknown as Fragile X syndrome (FXS), so dubbed for its characteristicmutation on the X chromosome, or Escalante's syndrome. Manifestationsof this disease in patients usually include a characteristic longfacial pattern, tooth and jaw misalignment, musculoskeletalabnormalities, or autism.
|
| 02/21/2008 01:00 AM |
| CME LLC Offers Education To Help Medical Professionals Better Recognize Adult ADHD |
|
CME LLC, a leading provider of fully accredited continuing medical education programs since 1978, today announced a new interactive educational program designed to increase recognition of the complexities and complications often encountered when diagnosing and treating patients with adult ADHD. The presentation of adult ADHD is often complicated by the presence of comorbid conditions such as depression, anxiety, bipolar disorder and substance abuse.
|
| 02/19/2008 04:00 AM |
| Nonstimulant Medication Is A Safe And Effective Alternative For ADHD Treatment In Children With Fragile X Syndrome |
|
Fragile X syndrome (FXS) is the most common hereditary form of mental retardation. Many children with FXS also suffer from attention deficit and/or hyperactivity disorder (ADHD), which complicates social relationships at home and at school.
|
| 01/30/2008 01:00 AM |
| Probable Cause Identified Of Age Differences In Stimulant Response |
|
In young children, psychostimulants relieve symptoms of Attention Deficit Disorder, yet in adolescents and adults, those same medications can cause euphoria and are often abused.What is behind these differing drug responses?Temple University scientists have identified a potential molecular mechanism, the neurotrophin system comprised of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, as the cause of age differences in stimulant response.
|
| ADD / ADHD Products |
ADD / ADHD Services |
Learning Disability Resources | Famous ADD/HD People | ADD/ADHD News |
